Nature Reviews Disease Primers 4, Article number: 43 (2018) https://doi.org/10.1038/s41572-018-0041-4 Published online 08 November 2018
In the originally published version of this article, in Table 4, Ocrelizumab was incorrectly referred to as an anti-CD25 antibody. This has been corrected in the HTML and PDF versions of the article to an anti-CD20 antibody.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Filippi, M., Bar-Or, A., Piehl, F. et al. Author Correction: Multiple sclerosis. Nat Rev Dis Primers 4, 49 (2018). https://doi.org/10.1038/s41572-018-0050-3
Published:
DOI: https://doi.org/10.1038/s41572-018-0050-3
This article is cited by
-
Predictors of severity and outcome of multiple sclerosis relapses
BMC Neurology (2023)
-
Patterns of attention deficit in relapsing and progressive phenotypes of multiple sclerosis
Scientific Reports (2023)
-
Could Mathematics be the Key to Unlocking the Mysteries of Multiple Sclerosis?
Bulletin of Mathematical Biology (2023)
-
RNA Sequencing of CD4+ T Cells in Relapsing–Remitting Multiple Sclerosis Patients at Relapse: Deciphering the Involvement of Novel genes and Pathways
Journal of Molecular Neuroscience (2021)
-
Proposed minimal essential co-expression and physical interaction networks involved in the development of cognition impairment in human mid and late life
Neurological Sciences (2021)
